×

Stocks Amgen Inc

  • Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!

  • Winterizing Your Portfolio - A CNBC Special Report

    Stocks advanced Monday, rebounding off of their worst week since last March, as worries about Bernanke's confirmation subsided and investors scooped up bargains. Techs advanced ahead of earnings from Apple and Texas Instruments after the bell.

  • Investors await the slew of corporate earnings results this week. What should they be expecting? Dan Cook, senior market analyst at IG Markets, shared his market insights.

  • Winterizing Your Portfolio - A CNBC Special Report

    Stocks advanced Monday, rebounding off of their worst week since last March, as worries about Bernanke's confirmation subsided and investors scooped up bargains. Techs advanced ahead of earnings from Apple and Texas Instruments after the bell.

  • Winterizing Your Portfolio - A CNBC Special Report

    Stocks advanced Monday, rebounding off of their worst week since last March, as worries about Bernanke's confirmation subsided and investors scooped up bargains. Techs advanced ahead of earnings from Apple and Texas Instruments after the bell.

  • Winterizing Your Portfolio - A CNBC Special Report

    U.S. stock index futures pointed to a strong rebound Monday after Wall Street recorded its biggest losses since the end of October on Friday.

  • earnings_central_badge.jpg

    What follows is a roundup of corporate earnings reports for Monday, Jan.  25.

  • Housing is left in ruins in Morne Saint Lazare Delmas in Port-au-Prince,

    Major companies continued to pour support into the Haiti relief effort following last Tuesday's devastating earthquake, and the US Chamber of Commerce said corporate aid pledges had already exceeded $16 million by 11 am Eastern.

  • Cramer makes the call on viewers' favorite stocks.

  • Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!

  • As we first told you last week, investors are closely watching potential hot stocks as the JPMorgan Health Care Conference gets underway.

  • Markets closed lower on Tuesday as Wall Street fretted over a weak start to earnings season. Sam Stovall, chief investment strategist at Standard & Poor’s, shared his market outlook.

  • BlackRock is taking a slightly more conservative stance on the stock market for this coming quarter, as last year's spectacular returns are unlikely to be repeated, Bob Doll, Vice Chairman and global Chief Investment Officer for equities, told CNBC Tuesday.

  • Cash is King!  Whether you are a bull or a bear, having cash on hand helps companies weather downturns or invest in the future.  Here are the S&P 500 companies with the biggest cash positions.

  • microscope_200.jpg

    Normally things tend to slow down a bit between Thanksgiving and New Year's Day. But this week alone we've already seen two biopharma partnership deals in as many days. First Pfizer and Protalix and now AstraZeneca and Targacept.

  • The latest erectile dysfunction drug is showing promise of working even faster than those already on the market. Considering it's $3.5 billion market, what's the trade?

  • Since the March bottom, small caps have outperformed large caps, but in the last month, larger firms have come on stronger. So where should you put your money? Portfolio managers Mary Jane Matts of Fifth Third Large Cap Value Fund and Bob Sullivan of Satuit Capital Microcap Fund shared their insights.

  • Stocks opened lower on Tuesday, after a sharp rally in the prior session. Where should investors be looking and how should they play the markets? David Spika, VP and investment strategist at WHG Funds and Bill Smead, CEO and CIO of Smead Capital Management shared their outlooks.

  • Intel's headquarters in Santa Clara, California.

    New York Attorney General Andrew Cuomo filed some salacious charges this morning, accusing Intel of using "illegal threats and collusion" to control the microprocessor market.

  • Over the past few days there's been a remarkable confluence of newsflow, most of it positive, out of biopharma. First the bad news.